http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0185210-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34bd4e87ecbca17f16d460ca394e60f9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 |
| filingDate | 1985-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d920a4cd20ad7d3c3f5cf3b1587a4e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f33a6e8b890617b740cfb137ed059e6 |
| publicationDate | 1986-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0185210-A2 |
| titleOfInvention | Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis |
| abstract | The invention relates to the use of dipeptide derivatives of the formula in which R represents a hydrogen atom, an alkyl radical having 1 to 6 carbon atoms, a cyclohexyl radical or a benzyl radical, and in Z represents one of the groups R 2 together with R 3 represents an additional bond or, if Z represents group (b), represents a hydrogen atom and in which R 4 and R 5 represent hydrogen atoms or alkyl radicals having 1 to 3 carbon atoms and R 5 also Can be phenyl and R 6 is hydrogen or methyl, or their pharmaceutically acceptable salts with acids for the manufacture of medicaments for the treatment of people suffering from amyotrophic lateral sclerosis ("ALS"). These medicaments are prepared in such a way that the compounds of the formula I can be administered to the ALS patients, in particular initially by infusion or injection, but then oral, rectal or percutaneous administration forms can also be used for further treatment. With this treatment, an improvement in the clinical symptoms is achieved in ALS patients, which persists even after stopping the medication. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2208148-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6515011-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7144899-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7084134-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-3820817-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-3820817-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0858262-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6528503-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0858262-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2208148-A |
| priorityDate | 1984-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.